1496551-70-2

Basic information

• Product Name: (2R,3R,4R,5R)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-chloro-4-Methyltetrahydrofuran-3-yl benzoate
• Synonyms: (2R,3R,4R,5R)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-chloro-4-Methyltetrahydrofuran-3-yl benzoate;IABYYJSVZGLSCK-RDWHIKKYSA-N
• CAS NO: 1496551-70-2
• Molecular Formula: C31H26ClN3O7
• Molecular Weight: 588.00704
• Mol File: 1496551-70-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 8.52±0.20(Predicted)
• CAS DataBase Reference: (2R,3R,4R,5R)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-chloro-4-Methyltetrahydrofuran-3-yl benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R,4R,5R)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-chloro-4-Methyltetrahydrofuran-3-yl benzoate(1496551-70-2)
• EPA Substance Registry System: (2R,3R,4R,5R)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-chloro-4-Methyltetrahydrofuran-3-yl benzoate(1496551-70-2)

Safety Data

• Hazardous Substances Data: 1496551-70-2(Hazardous Substances Data)

Usage

General Description

The chemical "(2R,3R,4R,5R)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-chloro-4-Methyltetrahydrofuran-3-yl benzoate" is a complex organic compound with a molecular structure consisting of a tetrahydrofuran ring, a benzoyloxy methyl group, and a benzamide derivative. It has a 4-chloro-4-methyl substitution on the tetrahydrofuran ring and a benzoyloxy methyl group attached to the 3rd carbon of the ring. Additionally, it contains a benzamide moiety at the 5th carbon of the ring, making it a unique and potentially biologically active molecule with potential applications in pharmaceuticals or organic chemistry research.

Upstream product

• 26661-13-2 4-N-benzoylcytosine 
• 879551-01-6 (4S,5R)-ethyl-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-meth-yl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide 
• 238096-55-4 N-(2-((1-trimethylsilyl)oxy)pyrimidin-4-yl)benzamide 

Downstream Products

• 1496551-77-9 (2R)-isopropyl 2-(((((2R,3R,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1613590-79-6 C₁₇H₁₆ClFN₂O₆ 
• 1613590-78-5 C₁₇H₁₅ClFIN₂O₅ 
• 1496551-72-4 1-((2R,3R,4R,5R)-3-chloro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1496551-71-3 C₂₄H₂₁ClN₂O₇ 

Relevant articles and documents

The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2′-α-chloro-2′-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors

Herein we describe the discovery of IDX21437 35b, a novel RP D-aminoacid-based phosphoramidate prodrug of 2′-α-chloro-2′-β-C-methyluridine monophosphate. Its corresponding triphosphate 6 is a potent inhibitor of the HCV NS5B RNA-dependent RNA polymerase (RdRp). Despite showing very weak activity in the in vitro Huh-7 cell based HCV replicon assay, 35b demonstrated high levels of active triphosphate 6 in mouse liver and human hepatocytes. A biochemical study revealed that the metabolism of 35b was mainly attributed to carboxyesterase 1 (CES1), an enzyme which is underexpressed in HCV Huh-7-derived replicon cells. Furthermore, due to its metabolic activation, 35b was efficiently processed in liver cells compared to other cell types, including human cardiomyocytes. The selected RP diastereoisomeric configuration of 35b was assigned by X-ray structural determination. 35b is currently in Phase II clinical trials for the treatment of HCV infection.